Zuma7 shows that, in spite of cross over in >50%, there is an OVERALL SURVIVAL BENEFIT for CAR-T (Axi-Cel) versus chemo+transplant for #DLBCL #lymphoma - the NEJM Paper is online! bit.ly/43Fpxmn #lymsm Great to have been a part of this practice-changing trial.

We are thrilled that our recent study lead by Felix Bayerl is out in Immunity today. We addressed the question how cDC1 dysfunction is regulated in tumors and to which extent this contributes to cancer immune evasion. It is Open Access!👇 cell.com/immunity/fullt… A short 🧵:

#Glofitamab now US FDA approved for #DLBCL after 2 prior lines! Highly potent (CR43%),FIXED course, durable responses. This is great for patients let's hope ROW follows! Proud to have contributed to the data underpinning this . #lymsm #ICML17 #ICMLugano bit.ly/3qS8C1F

#Glofitamab approved in Europe for r/r DLBCL. The CD20×CD3 bispecifics are the most potent single drugs so far tested in this indication, I hope they will be made available #lymsm globenewswire.com/news-release/2…

We are excited that our latest study on cDC1-mediated coordination of anti-cancer responses by tumor-infiltrating TCF1+stem-like CD8+ T cells, led by PhilippaMeiser is now published OPEN ACCESS in Cancer Cell! cell.com/cancer-cell/fu… 🧵👇1/n

Skin T cells, tolerance, and checkpoint control?! We loved this paper from Nik Joshi Martina Damo so much that Prof Frank Carbone came out of retirement to co-author this review!👩‍🔬👨‍🔬 nature.com/articles/s4159… nature Nature Immunology Doherty Institute

Share petermac.org/about-us/news-…

We’re hiring!! Please apply if you’re interested in joining a fun team studying T cell biology in cancer and infection! #TeamTpex Doherty Institute UniMelb MDHS jobs.unimelb.edu.au/en/job/914744/…

Very happy that our latest paper on regulation of DNGR-1-mediated cross-presentation is out in Cell Reports cell.com/cell-reports/f…

Our latest story is out in @CellPressImmunity today!! We show that Stat5 opposes Tox and rewires exhausted CD8s towards more durably protective effector-like states. Shout out to my co-authors, Parker Institute for Cancer Immunotherapy and E. John Wherry Key take-home messages in the 🧵⬇️ cell.com/immunity/ppt/S…

🚨Dendritic cell lovers!🚨 Mark in your calendar the 17th International symposium on DCs in #DC2024Barcelona (20-23 October 2024). Please, check the webpage dc2024barcelona.com with the preliminary program! Thanks to our fantastic speakers for accepting the invitation! 👇🏻👇🏻👇🏻

Online now @nature the final version of Sandra Nakandakari’s universal LIPSTIC paper! Thanks to Mempel Lab and the other reviewers for their very useful input. *Special* thanks to Kamphorst Lab for stepping in to help us out! nature.com/articles/s4158…

I am very excited to see this in print! New work from our lab defines an interferon-induced memory B cell subset during chronic viral infection. An awesome effort by Lucy Cooper Lucy Cooper & supported by our generous lab members & collaborators Monash Biomedicine Discovery Institute Immunity

Out now our review on #BispecificAntibodies Trends in Cancer!👉t.ly/L0BS0 We cover preclinical & clinical developments, trials data & challenges ahead A joy working w the dream team! Mercedes Herrera Giulia Pretelli Thiago M Steiner Lillian Siu Elena Garralda Jayesh Desai

Discover the latest on bispecific antibodies in cancer Trends in Cancer! 👉t.ly/L0BS0 Excited to see where the field will take us in the coming years! 🔬 A great team effort! Mercedes Herrera Giulia Pretelli Lewis Au Lillian Siu Elena Garralda Jayesh Desai

Bispecific antibodies: advancing precision oncology Trends in Cancer doi.org/10.1016/j.trec… 👉Bispecific antibodies are on the rise with promising data 👏Excellent in depth review ESMO - Eur. Oncology

Publication 🚨: very comprehensive & in-depth review on bispecific antibodies, a fast-rising field in oncology! Published Trends in Cancer by a⭐️team, including our postdocs Lewis Au & Thiago M Steiner as co-senior authors. Check it out 👇 Peter Mac Cancer Centre Peter Mac Research